ZA200803882B - Transdermal Therapeutic System - Google Patents

Transdermal Therapeutic System

Info

Publication number
ZA200803882B
ZA200803882B ZA200803882A ZA200803882A ZA200803882B ZA 200803882 B ZA200803882 B ZA 200803882B ZA 200803882 A ZA200803882 A ZA 200803882A ZA 200803882 A ZA200803882 A ZA 200803882A ZA 200803882 B ZA200803882 B ZA 200803882B
Authority
ZA
South Africa
Prior art keywords
therapeutic system
transdermal therapeutic
transdermal
therapeutic
Prior art date
Application number
ZA200803882A
Other languages
English (en)
Inventor
Paul M Gargiulo
Lane Roger Michael
Platt Beatrix
Theobald Frank
Wall Bettina
Original Assignee
Novartis Ag
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37716856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200803882(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Lohmann Therapie Syst Lts filed Critical Novartis Ag
Publication of ZA200803882B publication Critical patent/ZA200803882B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200803882A 2005-12-01 2008-05-07 Transdermal Therapeutic System ZA200803882B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74151105P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
ZA200803882B true ZA200803882B (en) 2009-03-25

Family

ID=37716856

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803882A ZA200803882B (en) 2005-12-01 2008-05-07 Transdermal Therapeutic System

Country Status (31)

Country Link
US (3) US20070128263A1 (ja)
EP (5) EP2292219B9 (ja)
JP (3) JP2009517468A (ja)
KR (7) KR20220156666A (ja)
CN (2) CN101312717A (ja)
AR (2) AR057152A1 (ja)
AT (1) AT11185U1 (ja)
AU (1) AU2006320919B2 (ja)
BR (2) BRPI0619758A2 (ja)
CA (1) CA2563110A1 (ja)
DE (2) DE202006021172U1 (ja)
DK (5) DK2292219T3 (ja)
EC (1) ECSP088469A (ja)
ES (1) ES2414455T3 (ja)
GT (1) GT200800075A (ja)
HK (1) HK1153646A1 (ja)
IL (4) IL191311A (ja)
MA (1) MA30022B1 (ja)
MY (2) MY151020A (ja)
NO (1) NO20082753L (ja)
NZ (1) NZ568273A (ja)
PH (2) PH12013500771A1 (ja)
PL (1) PL2292219T4 (ja)
PT (1) PT2292219E (ja)
RU (1) RU2450805C2 (ja)
SG (1) SG2014014989A (ja)
SI (1) SI2292219T1 (ja)
TN (1) TNSN08238A1 (ja)
TW (1) TWI389709B (ja)
WO (1) WO2007064407A1 (ja)
ZA (1) ZA200803882B (ja)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
BRPI1006655A2 (pt) * 2009-04-17 2016-02-10 3M Innovative Properties Co construção de adesivo de gel de silicone e métodos para a produção de uma construção de adesivo de gel de silicone
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
PL2493457T3 (pl) 2009-10-30 2018-01-31 Ix Biopharma Ltd Szybko rozpuszczalna stała postać dawkowana
WO2011073362A1 (en) 2009-12-18 2011-06-23 Novartis Ag Process for the preparation of optically active compounds using pressure hydrogenation
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
PL2515886T3 (pl) * 2009-12-22 2018-08-31 Luye Pharma Ag Przezskórny układ terapeutyczny do podawania rywastygminy lub jej pochodnych
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
RU2578971C2 (ru) * 2010-06-17 2016-03-27 Лтс Ломанн Терапи-Системе Аг Трансдермальное введение мемантина
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
JP2013537526A (ja) * 2010-07-21 2013-10-03 スリーエム イノベイティブ プロパティズ カンパニー 経皮接着剤組成物、デバイス、及び方法
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120046383A1 (en) * 2010-08-19 2012-02-23 Terumo Kabushiki Kaisha Silicone rubber composition
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
EP2468274B1 (de) * 2010-12-14 2015-07-01 Acino AG Transdermales therapeutisches System zur Verabreichung eines Wirkstoffs
KR101788802B1 (ko) * 2010-12-24 2017-10-20 주식회사 삼양바이오팜 리바스티그민을 함유하는 경피흡수제제
KR101054317B1 (ko) * 2011-01-28 2011-08-08 신신제약 주식회사 리바스티그민을 함유하는 경피흡수제제
KR101317158B1 (ko) * 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
KR20120130073A (ko) * 2011-05-20 2012-11-28 에스케이케미칼주식회사 리바스티그민 함유 패취
WO2012161489A2 (ko) * 2011-05-20 2012-11-29 에스케이케미칼 주식회사 리바스티그민 함유 패취
JP6102739B2 (ja) 2011-08-31 2017-03-29 東洋インキScホールディングス株式会社 貼付剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
KR101399035B1 (ko) * 2011-12-22 2014-05-28 주식회사 트랜스덤 리바스티그민을 함유하는 경피흡수제제
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
CN104136025B (zh) * 2012-02-28 2017-10-24 日绊株式会社 贴附剂
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151667A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150051559A1 (en) * 2012-04-05 2015-02-19 Sparsha Pharma International Private Limited Transdermal patch for treatment of dementia or alzheimer type dementia
WO2013187451A1 (ja) * 2012-06-12 2013-12-19 株式会社 ケイ・エム トランスダーム 貼付剤
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104582693A (zh) * 2012-08-15 2015-04-29 道康宁公司 多层药物递送系统
CN104602687A (zh) * 2012-09-03 2015-05-06 尼普洛外用药品株式会社 贴剂
KR20140038237A (ko) * 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US20140083878A1 (en) * 2012-09-21 2014-03-27 Mylan Inc. Transdermal drug delivery device
WO2014051128A1 (ja) * 2012-09-28 2014-04-03 株式会社 ケイ・エム トランスダーム 貼付剤
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
RU2560668C2 (ru) * 2013-03-04 2015-08-20 Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии" Трансдермальный седативный фармацевтический гель для лечения психоэмоциальных расстройств
CA2906796A1 (en) * 2013-03-15 2014-09-25 Nal Pharmaceuticals Ltd. Transdermal drug delivery system containing rivastigmine
AR095259A1 (es) * 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
TWI626953B (zh) * 2013-06-12 2018-06-21 Km Transderm Ltd Percutaneous absorption preparation
WO2014200072A1 (ja) 2013-06-12 2014-12-18 株式会社 ケイ・エム トランスダーム 皮膚貼付用粘着シートおよびそれを用いた経皮吸収製剤
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
TWI629066B (zh) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
EP3081211A4 (en) 2013-12-12 2017-10-11 Hisamitsu Pharmaceutical Co., Inc. Patch with cover member and patch kit with cover member
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
US9949935B2 (en) 2014-04-08 2018-04-24 Teikoku Pharma Usa, Inc. Rivastigmine transdermal compositions and methods of using the same
WO2015174502A1 (ja) 2014-05-15 2015-11-19 ニチバン株式会社 リバスチグミンを含有する貼付剤のための包装体
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
CN106456566B (zh) 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
EP4238580A3 (en) 2014-05-20 2023-10-25 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
WO2015179782A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104523656A (zh) * 2014-11-20 2015-04-22 美吉斯制药(厦门)有限公司 一种卡巴拉汀缓释透皮贴剂及其制备方法
DE102015107743A1 (de) 2015-05-18 2016-11-24 Bsn Medical Gmbh Silikongelbeschichtete adhäsive Schichtstruktur
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
JP6864968B2 (ja) 2016-08-22 2021-04-28 救急薬品工業株式会社 貼付剤
JP7236389B2 (ja) * 2016-12-20 2023-03-09 エルテーエス ローマン テラピー-ジステーメ アーゲー アセナピンを含有する経皮治療システム
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
KR102033686B1 (ko) * 2017-05-19 2019-10-18 보령제약 주식회사 도네페질을 함유하는 마이크로니들 경피 패치
US11389421B2 (en) 2017-09-05 2022-07-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of rivastigmine
BR112020018607A2 (pt) * 2018-03-13 2020-12-29 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone acrílico
WO2019175106A1 (en) * 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
EP3764998A1 (en) * 2018-03-13 2021-01-20 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
EP3810101A1 (en) 2018-06-19 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing rivastigmine
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
KR102590643B1 (ko) 2019-01-31 2023-10-17 히사미쓰 세이야꾸 가부시키가이샤 첩부제
JP2022540442A (ja) * 2019-07-09 2022-09-15 エルテーエス ローマン テラピー-ジステーメ アーゲー シリコーン含有ポリマーを含む活性剤含有層及びシリコーンゲル接着剤を含む皮膚接触層を含む経皮治療システム
BR112021023509A2 (pt) * 2019-07-09 2022-01-18 Lts Lohmann Therapie Systeme Ag Sistema terapêutico transdérmico compreendendo uma camada contendo o agente ativo compreendendo um polímero acrílico e uma camada de contato com a pele compreendendo um adesivo de gel de silicone
CN113616625B (zh) * 2021-08-26 2023-05-30 大连科翔科技开发有限公司 一种卡巴拉汀的长效透皮贴剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6316023B1 (en) 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
AU2002235155A1 (en) * 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
DE10103860B4 (de) 2001-01-30 2004-12-23 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
WO2003020289A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
DE10159745A1 (de) * 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
DK1509232T3 (da) * 2002-05-31 2009-02-23 Lundbeck & Co As H Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
PL376476A1 (en) * 2002-10-24 2005-12-27 Merz Pharma Gmbh & Co.Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
JP2007523121A (ja) 2004-02-19 2007-08-16 ノバルティス アクチエンゲゼルシャフト 血管性鬱病の処置のためのコリンエステラーゼ阻害剤の使用
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
EP2596889B1 (en) * 2011-11-23 2017-04-26 Sandvik Intellectual Property AB A cutting insert and a milling tool

Also Published As

Publication number Publication date
AU2006320919B2 (en) 2011-04-28
IL234364A (en) 2016-06-30
MY151020A (en) 2014-03-31
PH12013500772A1 (en) 2016-01-18
AR057152A1 (es) 2007-11-21
KR20180050441A (ko) 2018-05-14
US20130266633A1 (en) 2013-10-10
PH12013500772B1 (en) 2016-01-18
DK201300059U1 (da) 2013-04-29
DK201300014U1 (da) 2013-02-08
AU2006320919A1 (en) 2007-06-07
SG2014014989A (en) 2014-06-27
CA2563110A1 (en) 2007-06-01
IL250734A0 (en) 2017-04-30
RU2008126459A (ru) 2010-01-20
MY162986A (en) 2017-07-31
GT200800075A (es) 2010-06-01
EP2286802A1 (en) 2011-02-23
DK201300015Y4 (da) 2016-02-12
EP2292219B1 (en) 2013-06-12
NO20082753L (no) 2008-08-19
TW200732001A (en) 2007-09-01
DK201600113Y4 (da) 2017-06-09
JP2009517468A (ja) 2009-04-30
JP2016104737A (ja) 2016-06-09
KR20080071581A (ko) 2008-08-04
AT11185U1 (de) 2010-06-15
MA30022B1 (fr) 2008-12-01
DK201300059U3 (da) 2013-05-13
TNSN08238A1 (en) 2009-10-30
PH12013500771A1 (en) 2016-01-18
IL234291A (en) 2017-02-28
KR20210008440A (ko) 2021-01-21
TWI389709B (zh) 2013-03-21
DK201300014U3 (da) 2013-05-13
EP3235495A1 (en) 2017-10-25
EP2786748A1 (en) 2014-10-08
DE202006021172U1 (de) 2013-05-07
DE14163637T1 (de) 2015-06-03
EP2292219B9 (en) 2015-02-18
JP5938612B2 (ja) 2016-06-22
EP1959937A1 (en) 2008-08-27
CN101312717A (zh) 2008-11-26
ECSP088469A (es) 2008-07-30
ES2414455T3 (es) 2013-07-19
WO2007064407A1 (en) 2007-06-07
DK201300015U1 (en) 2013-02-08
IL191311A (en) 2015-02-26
JP2013177419A (ja) 2013-09-09
EP2292219A1 (en) 2011-03-09
DK2292219T3 (da) 2013-06-24
NZ568273A (en) 2011-06-30
KR20140072108A (ko) 2014-06-12
RU2450805C2 (ru) 2012-05-20
KR20170033449A (ko) 2017-03-24
CN102048713A (zh) 2011-05-11
HK1153646A1 (en) 2012-04-05
PL2292219T3 (pl) 2013-09-30
PT2292219E (pt) 2013-06-24
US20140134230A1 (en) 2014-05-15
AR097045A2 (es) 2016-02-17
KR20130143729A (ko) 2013-12-31
BRPI0619758A2 (pt) 2011-10-18
PL2292219T4 (pl) 2014-03-31
KR20220156666A (ko) 2022-11-25
JP6298034B2 (ja) 2018-03-20
DK201600113U1 (da) 2017-01-13
SI2292219T1 (sl) 2013-08-30
BR122013013162A2 (pt) 2015-06-30
US20070128263A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
IL250734A0 (en) Transdermal therapeutic system
HK1205935A1 (en) Non-lithotripsic kidney-stone therapy
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
GB0526291D0 (en) Therapeutic method
GB0509326D0 (en) Therapeutic compounds
GB0509573D0 (en) Therapeutic compounds
GB0515140D0 (en) Therapeutic device
GB0522881D0 (en) Therapeutic compounds
GB0509405D0 (en) Therapeutic compounds
GB0513747D0 (en) Therapeutic compounds
ZA200809004B (en) Autodestructive transdermal therapeutic system
GB0507003D0 (en) Therapeutic
GB0518235D0 (en) Therapeutic compounds
GB0518720D0 (en) Therapeutic combination
GB0501655D0 (en) Therapeutic use
ZA200710418B (en) Solid transdermal therapeutic system comprising UV absorber
GB0722015D0 (en) Transdermal therapy
GB0515580D0 (en) Therapeutic compounds
GB0511259D0 (en) Therapeutic utrasound system
GB0622285D0 (en) Transdermal therapy
GB0501657D0 (en) Therapeutic use
GB0518537D0 (en) Therapeutic use
GB0509932D0 (en) Therapeutic method
GB0521547D0 (en) Therapeutic method
GB0521540D0 (en) Therapeutic method